Does excessive body mass affect the rhGH therapy outcomes in GHD children?

Introduction: For 35 years, recombinant human growth hormone (rhGH) has been successfully used worldwide to treat children with short stature related to growth hormone deficiency (GHD). Growth hormone therapy requires an individual approach to the patient due to varying responses to the treatment. Excessive body weight is one of the factors influencing the response.

Primary response in GHD children treatment as a predictor for long-term therapy effectiveness therapy effectiveness.

Introduction: Short stature in growth hormone deficiency (GHD) can be treated with recombinant human growth hormone (rhGH), which is proven to be both safe and effective. However, a considerable number of patients does not achieve satisfying therapy outcomes.

Aim Of The Study: To evaluate the predictive effect of height increase in the first year of rhGH treatment on long-term therapy outcomes.